Predicting the functional consequences of genetic variants in co-stimulatory ligand B7-1 using in-silico approaches

Mathur, Riya; Sharma, Loveena; Dhabhai, Bhanupriya; Menon, Athira M.; Sharma, Amit; Sharma, Narendra Kumar; Dakal, Tikam Chand

doi:10.1016/j.humimm.2020.12.001

Cited by 2 publications

(1 citation statement)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The collection and analysis of data from millions of species, possibly billions of individuals, and many trillions of base pairs from multiple species are required for biological inquiry to be considered a true science (Al-Badri et al, 2018;Dakal et al, 2017a;Dakal et al, 2017b;Dhakar et al, 2022;Mathur et al, 2021;Menon & Dakal, 2020). As tools for high-throughput data processing, computers are perfectly suited to help this business.…”

Section: Discussionmentioning

confidence: 99%

Integrated Bioinformatics Approach Showed Linagliptin as Potential Drug for Prevention of Cardiac Arrest and Cancer

Dhabhai,

Dhakar,

Ranga

et al. 2023

MEDIN

View full text Add to dashboard Cite

The availability of Linagliptin as a DPP4 (Dipeptidyl-peptidase-4) inhibitor for the management of type 2 diabetes in individuals has been a recent development. The primary aim of the present investigation is to gain insights into the biological, physiological, and pharmacological mechanisms of action of the substance, as well as its impact on the cellular structure of human organisms. In this study, a range of genomics approaches and in-silico tools were employed, including PASS, SwissTargetPrediction, SwissADME, SEA, CLC-Pred, and DIGEP-Pred, to ascertain the physiochemical characteristics, pharmacokinetic attributes, biological targets, and biological activity of Linagliptin. Linagliptin is employed as a novel DPP4 inhibitor for the purpose of assisting those diagnosed with type 2 diabetes in managing their body's glycemic control. Nevertheless, our study revealed that Linagliptin has affinity for other molecular targets in humans, such as CHRM1, FAP, ALDH1A1, and PDE6D, thereby modulating their gene expression patterns. Prior studies have demonstrated that the administration of the medicine exerts an influence on renal and cardiovascular problems. Based on our research findings, we have developed a solid hypothesis that Linagliptin could potentially serve as an effective pharmaceutical intervention for the treatment of blood cancer and cardiac arrest.

show abstract